Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
Celldex Therapeutics
OHSU Knight Cancer Institute
Corvus Pharmaceuticals, Inc.
Seagen Inc.
Merck Sharp & Dohme LLC